{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=21", "query": { "condition": "Metastatic Colorectal Carcinoma", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1156, "total_pages": 116, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T07:13:16.911Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00271011", "title": "A Study of Mitomycin C, Irinotecan, and Cetuximab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2005-12", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00271011" }, { "nct_id": "NCT03368963", "title": "TAS102 in Combination With NAL-IRI in Advanced GI Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Non-Resectable Cholangiocarcinoma", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer", "Stage III Colorectal Cancer", "Stage III Gastric Cancer", "Stage III Pancreatic Cancer", "Unresectable Digestive System Adenocarcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-01-30", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368963" }, { "nct_id": "NCT03597581", "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer", "Gastrointestinal Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Gastric Cancer", "Gastric Neoplasm", "KRAS Mutation-Related Tumors", "CRC", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "ompenaclid", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inspirna, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2018-06-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 17, "location_summary": "Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03597581" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT04044430", "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer", "Stage III Colorectal Cancer", "Stage III Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Colorectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Colorectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Colorectal Cancer", "Stage IIIC Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Colorectal Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Rectal Cancer", "Stage IVC Colon Cancer", "Stage IVC Colorectal Cancer", "Stage IVC Rectal Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-31", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044430" }, { "nct_id": "NCT02286492", "title": "Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02286492" }, { "nct_id": "NCT05743036", "title": "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "ZN-c3", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2023-02-27", "completion_date": "2025-07-09", "has_results": false, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 3, "location_summary": "Los Angeles, California • Merriam, Kansas • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Merriam", "state": "Kansas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743036" }, { "nct_id": "NCT00408772", "title": "Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiofrequency ablation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2007-06", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2017-06-09", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408772" }, { "nct_id": "NCT05733000", "title": "CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Lung Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Urothelial Carcinoma", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Biliary Tract Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Lung Adenocarcinoma", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Biliary Tract Carcinoma", "Refractory Colorectal Carcinoma", "Refractory Gastroesophageal Junction Adenocarcinoma", "Refractory Lung Adenocarcinoma", "Refractory Ovarian Carcinoma", "Refractory Pancreatic Carcinoma", "Refractory Urothelial Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Devimistat", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2023-03-08", "completion_date": "2030-03-04", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733000" }, { "nct_id": "NCT00436072", "title": "ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "ZD6474", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2007-02", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-16T07:13:16.911Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436072" } ] }